Scenic Biotech

Over Scenic Biotech

Scenic Biotech's lead program addresses lysosomal storage disorders and neurodegeneration. A first in class break through that is about to enter clinical development. Scenic's robust pipeline for neurometabolic diseases is derived from its proprietary Cell-Seq discovery platform. In addition, the platform is leveraged through strategic R&D collaborations with Genentech, BMS, Alnylam and Ono. By unlocking new pathways in the genome, Scenic Biotech is developing a range of modifier therapies to help patients.

Trefwoorden

• Biology
• Biotechnology
• Disease
• Drug Development
• Drug Discovery
• Immuno-Oncology
• Medicine
• Metabolic Disease
• Neurological Disease
• Oncology
• Orphan Disease
• Pharmaceuticals
• Platform Technology
• Rare Disease
• Science
• Technology

Adres

• Hoofdkantoor

  Science Park 3011098XH AmsterdamNoord-Holland, Nederland

Team per functiegebied

Gebaseerd op 34 openbare functieprofielen, stand van 4 september 2026.

• Research / R&D12
• Other / Unclassifiable7
• Executive / C-Suite4
• Finance / Accounting3
• HR / People / Recruiting2
• Legal / Compliance2
• Administrative / Office1
• Data / Analytics / Science1
• Founder / Owner1
• Sales1